title: Antiretroviral therapy 2010 update: current practices and controversies.
abstract: Over the past four years, significant advances have been made in human immunodeficiency virus (HIV) therapy. In addition to the release of two new classes of antiretrovirals, our understanding of the older antiretrovirals continues to improve. Multiple combination pills have been brought to market, simplifying the regimens for patient ease. New controversies have arisen, notably the role of antiretrovirals in the chronic inflammatory state that HIV infection produces, which may lead to excess cardiac, renal, and hepatic mortality. The optimum time to initiate antiretroviral therapy remains unknown but clinicians are treating HIV infection earlier in its course. In this article, we review these and other new issues relating to the care of the HIV patient.
authors.affiliation: Section of Infectious Diseases, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Grant
authors.forename: Rafik
authors.initials: R
authors.lastname: Samuel
authors.forename: Robert L
authors.initials: RL
authors.lastname: Bettiker
authors.forename: Byungse
authors.initials: B
authors.lastname: Suh
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000473:pathology; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D023581:HIV Fusion Inhibitors; D018894:Reverse Transcriptase Inhibitors